23MB031N Immunotherapy: Using 12 Chemokine Signature to Select Sting Agonist and TIL Treatments for Solid Tumors | Moffitt

Home
Research Science
Academic and Industry Partnerships
Office of Innovation
Available Technologies
Diagnostics
23MB031N Immunotherapy: Using 12 Chemokine Signature to Select Sting Agonist and TIL Treatments for Solid Tumors

FOR MORE INFORMATION ON THIS TECHNOLOGY, PLEASE CONTACT OUR OFFICE

The Innovation Office
InnovationMarketing@Moffitt.org
(813) 745-6828